Execution Resilient Through Regulatory Disruption; Growth and Margins May Accelerate Together in 2H26
AI summary card
Execution Resilient Through Regulatory Disruption; Growth and Margins May Accelerate Together in 2H26
Goldman Sachs reiterates its Buy rating on JD Health International, believing that strong pharmaceutical growth, a recovery in nutrition products, and improved operating efficiency will support better second-half results.
- Management maintained FY26 revenue growth guidance of high-single-digit to high-teens YoY and raised its operating profit growth expectation to more than 30% YoY.
- The pharmaceuticals business further accelerated in 2Q26, and management expects the strong trend to continue into 2H26.
- Nutrition and health products were affected by tighter regulation, but are expected to stabilize in 3Q26 and recover in 4Q26; the company said its market share is still rising.
- Gross-margin improvement, better monetization efficiency, and operating leverage are expected to drive operating-margin expansion, despite continued AI investment.
- The target price was reduced from HK$65 to HK$59, mainly due to lower revenue forecasts and a lower target valuation multiple; the Buy rating is maintained.
Report interpretation
Overview
Goldman Sachs maintained a positive view following JD Health International's 1H26 results and non-deal roadshow. The report believes the company has continued to demonstrate strong execution and share-gain capability amid regulatory uncertainty surrounding nutrition and health products and GLP-1-related products, with revenue growth likely to accelerate in 2H26 and margins also having room to expand.
Core views
Pharmaceuticals growth accelerated in 2Q26 and was driven by a broader product mix; management remains confident that momentum will continue in 2H26.Nutrition and health products were affected in 2Q26 by regulatory scrutiny of cross-border supplements, functional nutrition-product advertising, and origin claims; they are expected to stabilize in 3Q26 and rebound in 4Q26 as brands resume marketing.Medical devices were affected in 2Q26 by a high base from subsidies, while a lower base in 2H26 should help improve growth.Higher gross margin, scale efficiencies, improved advertising and platform monetization, and AI-driven operating optimization are expected to support continued operating-margin expansion.AI commercialization focuses on a closed loop encompassing customer acquisition, health management, and product conversion, while helping brands optimize traffic-acquisition and promotional-budget allocation.The company's primary capital-allocation options are share buybacks, dividends, and M&A; it repurchased approximately US$110mn of shares in 2Q26.
Analysis framework
The report assesses the company by combining 1H26 results, management's updated FY26 guidance, segment growth trends, margin drivers, and forward-looking financial forecasts, and derives its 12-month target price using target P/E valuation.
Methodology notes
Target price determined using average 2026E-2027E P/E
The report applies an average 22x P/E multiple for 2026E-2027E to derive a 12-month target price of HK$59, compared with 25x previously.
Gross-margin improvement and expense efficiency drive margin expansion
The report expects scale effects, stronger monetization, and AI-enabled operations to offset part of the pressure from continued investment and lift operating margins.
Growth trajectory of pharmaceuticals, nutrition and health products, and medical devices
Pharmaceuticals are the main growth engine in the second half; nutrition and health products are expected to stabilize before recovering, while medical devices should benefit from a lower base.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- JD Health International（6618.HK）Covered Company
- Strengths
- Strong pharmaceuticals momentum; the online healthcare platform has advantages in scale, compliance, and consumer trust; market share in nutrition and health products continues to rise; ample cash and improving capital allocation; AI can optimize health services, conversion, and advertising efficiency.
- Weaknesses
- Near-term pressure on nutrition and health product growth; revenue forecasts have been reduced; AI-related investment may pressure near-term expense ratios.
- Comparison
- The company stated that in 2Q26, when industry nutrition and health product YoY growth turned negative, JD Health remained one of the key platforms sustaining positive YoY growth; its CPAP device return rate is approximately 10%, below the industry level of approximately 25%.
- Risks
- Pharmaceutical or non-pharmaceutical sales below expectations, intensifying competition from online pharmacies, instant retail, and livestreaming e-commerce, prolonged regulatory changes, and AI and instant-delivery investment weighing on margins.
Key data
- 12-month target priceHK$59.00Reduced from HK$65; Buy rating maintained.
- Share price at report dateHK$39.50Implies potential upside of 49.4%.
- FY26 revenue forecastRMB85,721.7 millionUp 16.7% YoY; approximately 1%-3% below the prior forecast.
- FY26 EBITDA forecastRMB5,694.6 millionUp 39.6% YoY, with EBITDA margin expected at 6.6%.
- FY26 operating profit growth guidanceMore than 30% YoYManagement's updated earnings outlook.
- FY26 EPS forecastRMB2.17Raised from the prior forecast of RMB2.09.
- FY26 forecast P/E15.7xCalculated using the report's financial forecast methodology.
- 2Q26 share repurchasesApproximately US$110mnReflects management's commitment to enhancing shareholder returns and capital efficiency.
- CPAP device return rateApproximately 10%Management said this is below the industry level of approximately 25% following AI-enabled service enhancements.
Impact & implications
The core investment thesis is that regulatory disruption has not changed the company's competitive position in pharmaceuticals and nutrition and health products. If nutrition and health products stabilize in 3Q26 and recover in 4Q26 as management expects, while pharmaceuticals growth remains strong, both revenue growth and margins could improve in 2H26. The lower valuation has reduced the target price, but the report believes the current share price offers an attractive risk-reward profile.
Risks
- Pharmaceutical or non-pharmaceutical sales growth below expectations.
- Continued or intensified regulatory uncertainty related to nutrition and health products, cross-border supplements, and GLP-1-related products.
- Higher-than-expected investment in AI and instant delivery, resulting in less-than-expected margin improvement.
- Intensifying competition from online pharmacies, O2O, and livestreaming e-commerce, creating subsidy and pricing pressure.
- Further valuation de-rating of the sector and internet stocks.
What to watch
- Sustainability of pharmaceuticals growth and breadth of the product mix in 2H26.
- Signs of stabilization in nutrition and health products in 3Q26 and the pace of recovery in 4Q26.
- Magnitude of growth improvement in medical devices from a lower base.
- Quarterly changes in gross margin, operating margin, and expense efficiency.
- Quantifiable AI results in return rates, advertising efficiency, health management, and product conversion.
- Capital-allocation actions such as buybacks, dividends, or M&A.